Your shopping cart is currently empty

SLC3037 is an NLRP3 inhibitor that prevents the binding or oligomerization of NLRP3 with NEK7, thereby inhibiting inflammasome activation triggered by MSU and other activators. It is suitable for research related to gout, cardiovascular diseases, metabolic syndrome, or neurodegenerative diseases.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | SLC3037 is an NLRP3 inhibitor that prevents the binding or oligomerization of NLRP3 with NEK7, thereby inhibiting inflammasome activation triggered by MSU and other activators. It is suitable for research related to gout, cardiovascular diseases, metabolic syndrome, or neurodegenerative diseases. |
| In vitro | SLC3037 (1-10 μM, 5 h) exhibits a dose-dependent inhibitory effect on IL-1β in bone marrow-derived macrophages (BMDMs) induced by lipopolysaccharide and MSU. |
| Formula | C29H35N7OS |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.